Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
RNA-seq (gene expression) · mouse · 46 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 46 samples: 46 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cellsNature · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE260816_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1082777 and SRA study SRP492898. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 22 samples read as cases, 4 as controls.
How we read this: Read from 46 sample titles: 46 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8124966 blood_ctrl_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124967 blood_ctrl_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124968 blood_tigitlalapg_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124969 blood_tigitlalapg_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124970 blood_tigit2b_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124971 blood_tigit2b_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124972 blood_tigit2a_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124973 blood_tigit2a_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124974 tumor_ctrl_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124975 tumor_ctrl_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124976 tumor_tigitlalapg_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124977 tumor_tigitlalapg_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124978 tumor_tigit2b_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124979 tumor_tigit2b_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124980 tumor_tigit2a_ADT_EXP_anti_TIGIT_monoTx_batch1
- GSM8124981 tumor_tigit2a_mRNA_EXP_anti_TIGIT_monoTx_batch1
- GSM8124982 blood_ctrl_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124983 blood_ctrl_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124984 blood_PDL1_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124985 blood_PDL1_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124986 blood_tigit2b_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124987 blood_tigit2b_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124988 blood_tigit2a_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124989 blood_tigit2a_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124990 blood_PDL1tg2b_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124991 blood_PDL1tg2b_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124992 blood_PDL1tg2a_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124993 blood_PDL1tg2a_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124994 tumor_ctrl_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124995 tumor_ctrl_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124996 tumor_PDL1_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124997 tumor_PDL1_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8124998 tumor_tigit2b_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8124999 tumor_tigit2b_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8125000 tumor_tigit2a_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8125001 tumor_tigit2a_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8125002 tumor_PDL1tg2b_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8125003 tumor_PDL1tg2b_mRNA_EXP_anti_TIGIT_comboTx_batch2
- GSM8125004 tumor_PDL1tg2a_ADT_EXP_anti_TIGIT_comboTx_batch2
- GSM8125005 tumor_PDL1tg2a_mRNA_EXP_anti_TIGIT_comboTx_batch2
+ 6 more — browse all 46 samples with per-sample file links →
- GSE292146 Tractable mouse TNBC models capture the heterogeneous tumor immune microenvironment and adaptation to PD-L1 blockade 38 samples shares pd-l1, blockade
- GSE236258 Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation 15 samples shares pd-l1, blockade
- GSE238087 Nanodrug modified with engineered cancer cell membrane targets CDKs to activate PD-L1 antibody immunotherapy against liver metastasis of immune-desert colon cancer 12 samples shares pd-l1, antibody
- GSE310954 Remodeling of Suppressive Melanoma Microenvironments by Particle-Mediated Modulation of the STING/IL-6/PD-L1 Axis Improves Tumor Immunity and Survival 11 samples shares pd-l1, improves
- GSE220901 TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation 168 samples shares pd-l1, blockade
- GSE325544 Loss of TET function in T regulatory cells yields ex-Treg cells biased toward T follicular helper cells, causing autoimmune diseases through autoantibody production 12 samples shares antibody, treg
- GSE250165 PD1 blockade improves survival and CD8+ cytotoxic capacity, without increasing inflammation, during normal microbial experience in old mice 14 samples shares improves, blockade
- GSE304155 HE4 regulates anticancer immune evasion by upregulating PD-L1 expression on macrophages through the IFN-γR-STAT3 axis [LLC tumors, scRNA-seq] 6 samples shares pd-l1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.